Chunghwa Chemical Synthesis & Biotech

Company Description

CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company manufacturing and distributing biotechnology and chemical synthetic products. The company's main businesses include biotechnology products (e.g., pravastatin, rapamycin, tacrolimus) and non-biotechnology products (e.g., methocarbamol, guaifenesin), applied in drugs for various treatments including cough, diabetes, cardiovascular diseases, high blood pressure, and immune system diseases. It operates in domestic and overseas markets, including Asia, the Americas, and Europe. In the last fiscal year, the company had a market cap of $73 million, profits of $12 million, and revenue of $41 million.

Analysis

ANALYSIS: With an Obermatt 360° View of 8 (better than 8% compared with alternatives), overall professional sentiment and financial characteristics for the stock Chunghwa Chemical Synthesis & Biotech are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for Chunghwa Chemical Synthesis & Biotech. The consolidated Value Rank has a low rank of 34 which means that the share price of Chunghwa Chemical Synthesis & Biotech is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 66% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 1, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 1% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 39, which means that the company has a riskier financing structure than 61% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 44, which means that professional investors are more pessimistic about the stock than for 56% of alternative investment opportunities. ...read more

Country

Taiwan

Industry Pharmaceuticals

Size X-Small

Website ccsb.com.tw

Index

FTSE Taiwan

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.